Cytosorbents Corporation (CTSO) Bundle
An Overview of Cytosorbents Corporation (CTSO)
General Summary of Cytosorbents Corporation (CTSO)
Cytosorbents Corporation, founded in 1997, is a critical care immunotherapy company based in Princeton, New Jersey. The company specializes in blood purification technology aimed at treating severe inflammatory conditions. Its flagship product, CytoSorb, is designed to remove cytokines and other inflammatory mediators from the blood during critical illness. As of 2024, Cytosorbents has expanded its product offerings to include the DrugSorb-ATR device, which is intended for drug removal in cases of overdose or toxicity.
In 2024, Cytosorbents reported total revenues of approximately $29.07 million for the nine months ended September 30, marking a 5% increase from approximately $27.68 million in the same period of 2023. Product sales accounted for approximately $26.44 million, which reflects an 11% increase from $23.74 million in 2023. The growth in sales is attributed to a 16% increase in distributor sales and an 8% increase in direct sales.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, Cytosorbents Corporation reported a gross profit of approximately $18.35 million, an increase from $17.08 million in the same period of 2023. The company's product gross margins stood at approximately 69%, down from 71% in the prior year due to production slowdowns and manufacturing issues.
Research and development expenses significantly decreased to approximately $5.62 million, down 52% from $11.63 million in 2023. This reduction was primarily due to the completion of the STAR-T clinical trial. Selling, general, and administrative expenses also saw a decline, totaling approximately $23.15 million for the nine months ended September 30, 2024, compared to $24.36 million in the prior year.
Despite the increase in revenue, the company reported a net loss of approximately $12.84 million for the nine months ended September 30, 2024, compared to a net loss of $22.67 million for the same period in 2023. The total accumulated deficit reached approximately $295.34 million as of September 30, 2024.
| Financial Metric | 2024 (9 Months Ended Sept 30) | 2023 (9 Months Ended Sept 30) |
|---|---|---|
| Total Revenues | $29.07 million | $27.68 million |
| Product Sales | $26.44 million | $23.74 million |
| Gross Profit | $18.35 million | $17.08 million |
| Net Loss | $12.84 million | $22.67 million |
| Accumulated Deficit | $295.34 million | $276.67 million |
Introduction to Cytosorbents as a Leader in the Industry
Cytosorbents Corporation is recognized as a leader in the blood purification market, particularly in critical care settings. The company's innovative technologies, such as the CytoSorb device, have garnered attention for their effectiveness in managing severe inflammatory responses in critically ill patients. Cytosorbents has established a robust presence in international markets, with significant sales in countries such as Germany, Switzerland, and Austria, among others. The company’s commitment to advancing its product pipeline, particularly with the upcoming FDA submission for DrugSorb-ATR, positions it well for future growth and leadership in the healthcare sector.
To understand more about Cytosorbents Corporation and its strategic initiatives, readers are encouraged to explore further details below.
Mission Statement of Cytosorbents Corporation (CTSO)
Mission Statement Overview
The mission statement of Cytosorbents Corporation (CTSO) serves as a guiding principle for the company's long-term goals and strategic direction. It reflects the organization's commitment to delivering innovative medical solutions, particularly in critical care settings. This mission emphasizes the development and commercialization of its flagship product, CytoSorb, aimed at improving patient outcomes through advanced therapeutic technologies.
Core Component 1: Innovation
Cytosorbents Corporation prioritizes innovation as a cornerstone of its mission. This is evident in the continuous development of its CytoSorb device, which is designed to remove cytokines and other inflammatory mediators from the bloodstream during critical illness.
In the nine months ended September 30, 2024, the company reported total revenues of approximately $29,071,000, marking a 5% increase compared to $27,681,000 in the same period in 2023 . The growth was driven by an 11% increase in product sales, which reached $26,444,000 . This revenue growth showcases the company's commitment to innovation and market penetration.
Core Component 2: Quality
The commitment to quality is fundamental to Cytosorbents' mission. The company ensures that its products meet stringent safety and efficacy standards. In Q3 2024, the gross profit margin was approximately 61%, highlighting the effective management of production and operational costs .
Furthermore, the company has invested heavily in research and development, with expenses totaling $5,619,000 for the nine months ended September 30, 2024, a significant decrease from $11,632,000 in the prior year due to the completion of clinical trials . This focus on maintaining high-quality standards while managing costs reflects the company's commitment to delivering superior products.
Core Component 3: Patient Outcomes
Enhancing patient outcomes is at the heart of Cytosorbents' mission. The company aims to provide healthcare professionals with effective tools to treat critically ill patients. The CytoSorb device has been granted Emergency Use Authorization (EUA) by the FDA for use in patients with COVID-19 and respiratory failure, thereby demonstrating its clinical relevance and potential impact on patient care.
In the nine months ended September 30, 2024, the company reported a net loss of approximately $12,835,000, a decrease from $22,672,000 in the same period in 2023, indicating improved operational efficiency . This reduction in losses suggests that the company is making strides toward achieving its mission of improving patient outcomes while also working towards financial sustainability.
| Financial Metric | Q3 2024 | Q3 2023 | Year-over-Year Change |
|---|---|---|---|
| Total Revenue | $9,390,388 | $8,810,847 | +7% |
| Gross Profit | $5,281,615 | $5,606,866 | -6% |
| Research & Development Expenses | $1,851,230 | $3,749,197 | -51% |
| Net Loss | $2,334,091 | $9,193,520 | -75% |
Vision Statement of Cytosorbents Corporation (CTSO)
Vision Statement of Cytosorbents Corporation (CTSO)
The vision statement of Cytosorbents Corporation focuses on enhancing patient outcomes through innovative medical technology, particularly in critical care and organ support. The company aims to lead in the development of advanced medical devices that improve treatment and management of severe conditions.
Innovation and Leadership in Medical TechnologyCytosorbents Corporation is committed to being at the forefront of innovation in medical technology. This commitment is demonstrated by its focus on developing products like CytoSorb, which is designed to remove cytokines and other inflammatory mediators from the blood, thereby improving patient outcomes in critical care settings.
Global Reach and ImpactThe vision includes expanding its global footprint, enabling access to life-saving therapies in various international markets. As of September 30, 2024, Cytosorbents reported total revenues of approximately $29.1 million for the nine-month period, representing a 5% increase from $27.7 million in the same period of 2023.
| Financial Metrics | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Total Revenues | $29,071,000 | $27,681,000 |
| Product Sales | $26,444,000 | $23,736,000 |
| Grant Income | $2,627,000 | $3,945,000 |
| Gross Profit | $18,355,000 | $17,081,000 |
| Net Loss | $(12,835,098) | $(22,672,487) |
Cytosorbents’ vision emphasizes a strong commitment to patient care and improving quality of life through its innovative therapies. The company's focus on research and development is evident with approximately $5.6 million spent on R&D for the nine months ended September 30, 2024, a significant decrease from $11.6 million in the same period of 2023, reflecting strategic prioritization of high-impact projects.
Strategic Partnerships and CollaborationsThe company aims to foster strategic partnerships with healthcare providers, regulatory bodies, and research institutions to enhance its product offerings and market penetration. This collaborative approach is crucial for achieving its vision of being a leader in critical care technology.
Sustainability and Ethical PracticesCytosorbents Corporation is also dedicated to sustainability and ethical practices in its operations, aligning its business strategies with broader healthcare goals. As of September 30, 2024, the company's accumulated deficit stood at approximately $295.3 million, highlighting the need for sustainable growth strategies.
Future OutlookLooking ahead, Cytosorbents aims to leverage its innovative technologies to address unmet medical needs globally, continuing its mission to improve patient outcomes through advanced medical solutions.
Core Values of Cytosorbents Corporation (CTSO)
Strong Commitment to Innovation
The core value of innovation at Cytosorbents Corporation (CTSO) reflects the company's dedication to advancing medical technology and improving patient outcomes. This commitment is exemplified through ongoing research and development initiatives aimed at enhancing their flagship product, CytoSorb.
In the nine months ended September 30, 2024, the company reported research and development expenses of approximately $5,619,000, a decrease from $11,632,000 in the same period of the previous year. This reduction was primarily due to the completion of the STAR-T clinical trial in December 2023, allowing for a reallocation of resources towards new innovative projects.
Additionally, the company has received substantial funding for its innovative projects, with ongoing contracts funded by governmental agencies such as the National Institutes of Health and the U.S. Department of Defense. Overall, grant-funded programs have received approximately $15.8 million, $4.7 million, and $7.7 million in total funding for various initiatives.
Integrity and Transparency
Integrity and transparency are foundational values at Cytosorbents Corporation, guiding their interactions with stakeholders, including investors and regulatory bodies. The company prioritizes ethical practices in all business operations.
For example, in March 2024, Cytosorbents reported receiving approximately $880,000 from the approved sale of net operating losses and research and development credits from the State of New Jersey. This financial maneuver demonstrates the company's commitment to maintaining transparency in its financial dealings.
Furthermore, the company has consistently reported financial results in a timely manner, with total revenues of approximately $29,071,000 for the nine months ended September 30, 2024, up from $27,681,000 in the same period of 2023.
Focus on Quality and Safety
Cytosorbents places a strong emphasis on quality and safety in its product offerings. The company’s flagship product, CytoSorb, has undergone rigorous testing and regulatory scrutiny to ensure it meets the highest safety standards.
As of September 30, 2024, gross profit margins for CytoSorb products were approximately 61%, reflecting the company’s focus on maintaining quality while managing production costs. The company has also planned for a temporary slowdown in production to rebalance inventory levels, ensuring that quality is not sacrificed for volume.
Moreover, the company’s commitment to quality is evident from its proactive measures in managing resources and controlling expenditures to uphold safety standards across its operations.
Collaboration and Teamwork
Collaboration and teamwork are vital core values at Cytosorbents Corporation, fostering a culture of cooperation among employees and with external partners. The company actively encourages cross-functional collaboration to drive innovation and improve operational efficiency.
In the nine months ended September 30, 2024, Cytosorbents reported a loss from operations of approximately $(12,740,587), highlighting the challenges faced while navigating the complex healthcare landscape. However, the company remains committed to working collaboratively with its teams and partners to enhance product offerings and achieve strategic goals.
The ongoing engagement with strategic partners and distributors emphasizes the importance of teamwork in expanding the reach of their products globally. For instance, distributor sales increased by 16% for the same period.
Customer-Centric Approach
A customer-centric approach is a key value at Cytosorbents Corporation, focusing on understanding and meeting the needs of healthcare providers and patients. The company actively seeks feedback to refine its products and services.
In the three months ended September 30, 2024, total product sales reached approximately $8,612,795, driven by a direct sales increase of 21%. This growth underscores the company’s commitment to addressing customer needs effectively.
Furthermore, Cytosorbents has developed relationships with hospitals and healthcare providers across multiple countries, ensuring that their products are accessible and tailored to the specific requirements of each market.
| Core Value | Example Initiatives | Financial Data |
|---|---|---|
| Innovation | Funding from NIH, DOD; STAR-T trial completion | R&D expenses: $5,619,000 (2024) |
| Integrity and Transparency | Timely financial reporting, ethical practices | Total revenue: $29,071,000 (2024) |
| Quality and Safety | Rigorous product testing, inventory management | Gross margin: 61% |
| Collaboration and Teamwork | Cross-functional projects, strategic partnerships | Loss from operations: $(12,740,587) |
| Customer-Centric Approach | Feedback mechanisms, market accessibility | Total product sales: $8,612,795 |
Cytosorbents Corporation (CTSO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Cytosorbents Corporation (CTSO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Cytosorbents Corporation (CTSO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Cytosorbents Corporation (CTSO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.